New drug relieves symptoms of irritable bowel syndrome in females

October 31, 1999

ROCHESTER, MINN.-- A Mayo Clinic-led study found that a new drug called alosetron (ah-loss'-e-tron) improves pain relief and bowel function in women with irritable bowel syndrome (IBS). It specifically helped patients who experienced diarrhea or altered bowel habits, not patients with constipation.

"This is the first drug that not only normalizes bowel function but also relieves some of the pain and discomfort of this disorder," says the lead investigator, Michael Camilleri, M.D, a gastroenterologist at Mayo Clinic.

The muti-center study tested four doses of the medication and placebo (an inactive medication) in 370 patients. The study found that 70 percent of females taking a 1 mg. dose twice a day reported adequate relief of pain and discomfort over the 12 weeks of the study, compared to 30 percent taking a placebo. The women also reported significant improvement in bowel functions, including less frequency and urgency of bowel movements. Side effects of constipation and headache were reported in 20 percent and 10 percent of participants, respectively.

The study, reported in the journal Alimentary Pharmacology and Therapeutics, showed no benefits in either pain relief or bowel function for males.

IBS is one of the most common gastrointestinal disorders, affecting about 15 percent of the population. It appears to be much more common in women than men, based on numbers who seek medical attention for the problem. The cause of the disease, sometimes known as "spastic colon," is unknown although it is thought to involve nerves controlling sensation and contractions in the digestive system. Among common symptoms are abdominal pain, cramping, a bloated feeling, gas and diarrhea or constipation. It is one of the leading causes of lost work and school time.

Alosetron is a nerve receptor antagonist that has the effect of relaxing the colon and slowing the transit of food residue through the colon. Because of this, patients who reported symptoms of constipation due to IBS were excluded from this study.

The drug is not currently available to the public. However, the drug maker, Glaxo Wellcome Inc., is currently seeking approval from the Food and Drug Administration to market the drug in the United States.
-end-
Mike O'Hara
507-284-9522 (days)
507-284-2511 (evenings)
e-mail: newsbureau@mayo.edu

Mayo Clinic

Related Irritable Bowel Syndrome Articles from Brightsurf:

Giant spider provides promise of pain relief for irritable bowel syndrome
Molecules from the venom of one of the world's largest spiders could help University of Queensland-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

Mindfulness program may benefit patients with irritable bowel syndrome
Adults with irritable bowel syndrome experienced fewer gastrointestinal symptoms after they participated in a mindfulness program meant to reduce stress.

The Lancet Gasteroenterology & Hepatology: First clinical trial finds probiotic treatment with dead bacteria is better than placebo at alleviating symptoms of irritable bowel syndrome
Probiotic bacteria that have been killed by heat can significantly improve symptoms of irritable bowel syndrome (IBS) compared to placebo, and are not associated with any safety risk, according to a new 12-week, randomized, double-blind, placebo-controlled clinical trial with 443 patients published in The Lancet Gastroenterology & Hepatology journal.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.

HKBU discovers mechanisms underlying early life stress and irritable bowel syndrome
Researchers from Hong Kong Baptist University have found that the abnormal rise of a soluble protein called Nerve Growth Factor is a key factor linking early life stress to the development of irritable bowel syndrome.

Microbiome science may help doctors deliver more effective, personalized treatment to children with irritable bowel syndrome
To improve the treatment of children with irritable bowel syndrome (IBS), investigators have developed a sophisticated way to analyze the microbial and metabolic contents of the gut.

The Lancet Gastroenterology & Hepatology: Hypnotherapy could help relieve irritable bowel syndrome symptoms
Peer-reviewed / Randomised Controlled Trial / People Gut-directed hypnotherapy delivered by psychologists appears as effective in group or individual sessions, potentially offering a new treatment option for irritable bowel syndrome in primary and secondary care

Early source of irritable bowel syndrome discovered
Michigan State University scientists have identified an early cause of intestinal inflammation, one of the first stages of inflammatory bowel disease and irritable bowel syndrome, which afflict around 11 percent of the world's population.

Read More: Irritable Bowel Syndrome News and Irritable Bowel Syndrome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.